uPA、uPAR和肝癌的研究进展
出处
《内科》
2010年第2期178-179,共2页
Internal Medicine
基金
广西科学基金(桂科基0143059)
广西科技攻关基金(桂科攻0592007)
参考文献17
-
1Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease[J ]. Cull Vasc Pharmacol,2006,4 (2) : 101 - 116.
-
2Idell S, Coagulation, fibrinolysis, and fibrin deposition in acute lung injnry[ J]. Crit Care Med,2003,31 (4) :213 -220.
-
3Behrendt N. The urokinase receptor(uPAR) and the uPAR-associated protein(uPARP/Endo180) : membrane proteins engaged in matrix turnover during tissue remodeling [ J ]. Biol Chem, 2004,385 ( 2 ) : 103 - 136.
-
4Plesner T, behrendt N, Ploug M. Structure, function and expression On blood and bone marrow cells of the urokinase-type plasminogen activator receptor,uPAR [ J]. Stem Cells, 1997,15 (6) :398 - 408.
-
5Blasi F, Carmeliet P uPAR:aversatile signaling orchestrator[J]. Nat Rev Mol Cell Biol,2002 ,3(12) :932 -943.
-
6Chan CF, Yau TO, Jin DY, et al. Evaluation of Nuclear Factor-KB, Urokinase-Type Plasminogen Activator, and HBx and Their Clinicopathological Significance in Hepatocellular Carcinoma [ J ]. Clin Cancer Res,2004,10(12) :4140 -4149.
-
7Dano K, Rlomer J, Nielsen BS, et al. Cancer invasion and tissue remodeling-cooperation of protease system and cell type [ J ]. APMIS, 1999,107( 1 ) : 120 - 127.
-
8毛华,赵敏芳,袁爱力,赖卓胜,姜文奇.血管内皮生长因子对肝癌细胞侵袭能力和同质性粘附作用影响[J].肿瘤,2002,22(3):197-199. 被引量:16
-
9Zhou L, Hayashi Y, Itoh T, et al. Expression of urokinase-type plasminogcn activator, urokinase-type plasminogcn activator receptor and plasminogen activator inhibitor type-1 and type-2 in hcpatoceUular carcinoma [ J ]. Pathol Int, 2000,50 ( 5 ) : 392 - 397.
-
10Dubuisson L, Monvoisin A, Nielsen BS, et al. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma[ J]. J Pathol,2000,190 (2) :190 - 195.
二级参考文献18
-
1蔡建春,江绍基,陈治平.细胞粘附分子与肿瘤的浸润和转移[J].上海第二医科大学学报,1993,13(2):159-163. 被引量:8
-
2司履生,王一理.粘连分子及其在病理学中的作用[J].中华病理学杂志,1994,23(4):245-248. 被引量:19
-
3Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg, 2001,233:379-384.
-
4Yamada K, Soejima T, Sugimoto K, et al. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Jpn J Clin Oncol, 2001, 31 : 147-152.
-
5Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis analysis of 48 cases. Cancer, 2002, 95 : 588-595.
-
6Satoshi I, Takashi O, Junji F, et al. Radioherapy after transcatheter arterial chemoembilization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol, 2002, 25 : 189-193.
-
7Chen XP, Huang ZY. Surgical treatment of hepatocellular carcinoma in china Surgical techniques, indications, and outcomes. Langenbecks Arch Surg, 2005, 390:259-265.
-
8Sugimoto C, Saito A, Kikuzato M, et al. Angioeehographic evaluation of tumor thrombi and the effect of transcatheter arterial embolization in patients with hepatoeellular carcinoma. J Gastroenterol, 2002, 37: 363-368.
-
9Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol,2001, 16:660-665.
-
10毛华,陈宏.影响血管内皮生长因子表达的调控因素[J].国外医学(生理病理科学与临床分册),1999,19(4):282-284. 被引量:10
共引文献31
-
1毛华,黄纯炽,赵敏芳,宋卫生.p38MAPK信号传导通路调控VEGF诱导肝癌细胞黏附作用[J].世界华人消化杂志,2006,14(8):778-783. 被引量:17
-
2徐峰,欧阳志钢,张胜华,宋丹青,邵荣光,甄永苏.咖啡酸钠诱导内皮细胞凋亡及抑制癌细胞VEGF的表达(英文)[J].药学学报,2006,41(6):572-576. 被引量:7
-
3任淑萍,张秀英,李鹏,郑蓉,凌翎,李云.PCNA、IL-6和IL-1β在肿瘤组织中的表达[J].吉林大学学报(医学版),2006,32(6):953-955. 被引量:9
-
4吕小平,詹灵凌,姜海行,唐国都,梁水庭.肝细胞癌UPAR mRNA、VEGF和CD44v6的表达及临床意义[J].广西医学,2006,28(12):1855-1857. 被引量:6
-
5吕小平,詹灵凌,姜海行,唐国都,梁水庭.肝细胞癌尿激酶型纤溶酶原激活物受体mRNA、VEGF和c-erbB2的表达及意义[J].临床肝胆病杂志,2007,23(1):36-38. 被引量:4
-
6陈祖兵,沈世强,熊成龙,邬善敏,张训臣.肝细胞癌合并门静脉癌栓的外科治疗[J].腹部外科,2007,20(5):273-274. 被引量:1
-
7顾莉红,(综述),李凤华(审校).门静脉栓子的影像学研究进展[J].上海医学影像,2008,17(1):75-77. 被引量:9
-
8顾莉红,李凤华,李萍,朱彩霞,方华,杜晶,唐韵.实时灰阶超声造影评价肝移植术前门脉系统栓子的价值[J].中国医学影像技术,2008,24(4):557-559. 被引量:3
-
9邱继刚,樊嘉,刘银坤,周俭,代智,黄成.肝癌门静脉癌栓相关小分子的比较蛋白质组学分析[J].中华实验外科杂志,2009,26(2):181-183. 被引量:8
-
10苏永杰,夏锋.解剖性肝切除治疗肝细胞肝癌的理论依据和进展[J].实用临床医药杂志,2009,13(2):21-24. 被引量:6
-
1詹灵凌.uPA、uPAR和uPA/uPAR与肝癌发生的研究进展[J].内科,2009,4(3):429-431. 被引量:3
-
2廖君,王晓果,孔佩艳,张曦,易海,朱丽丹,刘耀,张诚,高蕾.血清uPA蛋白水平与急性髓系白血病的预后有关[J].第三军医大学学报,2016,38(12):1371-1373. 被引量:1
-
3张衣北,陈安民,郭风劲.UTI抑制骨肉瘤细胞侵袭与转移的实验研究[J].肿瘤防治研究,2006,33(5):355-357. 被引量:2
-
4余小平,糜漫天,朱俊东.Genistein对乳腺癌异种移植瘤的抑制作用及其与uPA表达变化的关系[J].第三军医大学学报,2005,27(11):1065-1067. 被引量:1
-
5廖君,孔佩艳,张曦,王晓果,易海,曾东风.骨桥蛋白促MV4-11白血病细胞uPA表达及信号通路研究[J].中国输血杂志,2015,28(11):1311-1313.
-
6许国强.纤维蛋白溶解系统与恶性肿瘤的浸润和转移(综述)[J].浙江医科大学学报,1995,24(2):93-96. 被引量:1
-
7张敬一,许顺江,史文海,张乃哲.实验性肺癌尿激酶型纤溶酶原激活物和抑制物的表达及意义[J].河北医科大学学报,2005,26(1):12-15.
-
8卢兴国,张桂娣,许元良,朱蕾,赵小英,张晓红.肝癌组织浸液尿激酶型和组织型纤溶酶原激活物的检测[J].基础医学与临床,2003,23(5):572-573. 被引量:1
-
9李文学,孙红.4-HPR联合顺铂对卵巢癌裸鼠移植瘤的抑制作用及其与VEGF、u-PA表达变化的关系[J].肿瘤,2008,28(4):305-309. 被引量:1
-
10潘超,李朱骁,杨坤兴,杨士勇,刘子君,席鹏程.胰腺癌患者血清VEGF-C及uPA水平检测的临床意义[J].中华胰腺病杂志,2016,16(5):345-347. 被引量:4